Towards personalised dosimetry in patients with liver malignancy treated with 90Y-SIRT using in vivo-driven radiobiological parameters

EJNMMI Physics

Table 1 Summary of estimated radiobiological parameters

Cancer type	\(T_{{\text{t}}}\) (days)	\(T_{{\text{p}}}\) (days)	\(T_{{\text{k}}}\) (d)	\(\alpha\) (Gy⁻¹)	\(\alpha {/}\beta\) (Gy)
Breast	49	124	23	0.009	5.00
PNET	47	166	22	0.009	11.2
Adrenocortical carcinoma	49	136	9.0	0.005	4.21
CRC	53	170	26	0.005	49.8
Cholangiocarcinoma	42	200	41	0.015	1.00
CRC	42	108	2.0	0.006	5.83
CRC	49	180	29	0.008	4.00
Rectal adenocarcinoma	46	300	27	0.200	5.91
Cholangiocarcinoma	48	348	48	0.100	1.53
CRC	47	87.0	10	0.010	6.45
Cholangiocarcinoma	47	59.0	1.0	0.001	5.98
Cholangiocarcinoma	48	336	23	0.050	1.00
Sigmoid adenocarcinoma	77	232	27	0.200	6.67
Breast	55	180	55	0.080	1.00
Prostate	56	250	56	0.100	2.00
CRC	56	97.0	50	0.030	4.29
PNET	23	134	49	1.000	2.20
PDAC	49	180	49	0.300	1.00
SBNET	59	300	59	0.800	8.89
Mesothelioma	56	157	39	0.010	8.13
PNET	48	200	48	0.124	12.4
HCC	50	90.0	10	0.003	2.78
Oesophageal	47	200	46	0.050	1.25
SBNET	54	86.0	13	0.022	11.1
NEC	41	87.0	1.0	0.028	1.40

\(T_{{\text{t}}}\), treatment time; \(T_{{\text{p}}}\), cell repopulation time; \(T_{{\text{k}}}\), kick-off time; PNET pancreatic neuroendocrine tumours, CRC colorectal cancer, PDAC pancreatic ductal adenocarcinoma, SBNET small bowel neuroendocrine tumours, HCC hepatocellular carcinoma, NEC neuroendocrine carcinoma.